INDIANAPOLIS, Oct. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that a pivotal Phase III study of Cialis® (tadalafil) tablets 5 mg for once daily use met its co-primary ...

Unichem Labs gets tentative USFDA nod for Tadalafil tablets The company has received the tentative approval from the United States food and Drug Administration for its Tadalafil tablets in the ...

Milestone reflects Eli Lilly and Company's commitment to bring new treatment options to millions of men who experience urological conditions INDIANAPOLIS, Sept. 21, 2012 /PRNewswire/ -- Eli Lilly and ...

Erectile dysfunction (ED) is a prevailing condition defined as the constant inability to obtain and sustain an erection sufficiently to achieve satisfactory sexual performance. 1 Although PDE5 ...

Pivotal studies support tadalafil for the treatment of benign prostatic hyperplasia and the treatment of both benign prostatic hyperplasia and erectile dysfunction in patients with both conditions.

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Tadalafil (Tadacip (20 mg)) is a ...

Eli Lilly and Company announced that a pivotal phase III study of Cialis (tadalafil) tablets 5 mg for once daily use met its co-primary endpoints, significantly improving measures of both erectile ...

Here in this cohort with high frequency of comorbidities and use of concomitant medications, we found that continuation rates over 6 months of treatment with tadalafil OaD were comparable across ...

Alembic Pharma gets USFDA nod for erectile dysfunction drug The approval from the United States Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for ...

-- Cialis becomes the first and only medication approved in the EU for both the signs and symptoms of benign prostatic hyperplasia and erectile dysfunction INDIANAPOLIS, Oct. 30, 2012 /PRNewswire/ -- ...